Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc.
Zeldes & Haeggquist, LLP Announces Investigation of Ventrus Biosciences, Inc. Business Wire SAN DIEGO -- April 8, 2013 Zeldes & Haeggquist, LLP, a shareholder and consumer rights litigation firm, has commenced an investigation into Ventrus Biosciences, Inc. (“Ventrus”), to determine whether it has violated securities laws by issuing false and misleading statements to its shareholders. Ventrus is a specialty pharmaceutical company that focuses on the development of prescription drugs for gastrointestinal disorders. On June 25, 2012, Ventrus announced the results of its Phase 3 placebo-controlled trial of its experimental drug iferanserin, also known as VEN 309. The trial results showed that VEN 309 failed to demonstrate an improvement in therapy in patients with hemorrhoidal disease, and Ventrus announced that it had no immediate plans to continue development of VEN 309. Upon this announcement, the price of Ventrus stock declined from as high as $12.26 per share on June 22, 2012 to as low as $4.27 on June 29, 2012, and continued to decline to as low as $2.06 per share on November 13, 2012. If you are a Ventrus Biosciences, Inc. (NASDAQ: VTUS) shareholder who purchased Ventrus common stock between December 17, 2010 and June 22, 2012, you may have claims under the securities laws. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber L. Eck at 619-342-8000, or by email at firstname.lastname@example.org. There is no cost to you. Our investigation focuses on whether statements made by Ventrus to the investing public regarding the effectiveness and commercial prospects for VEN 309 were materially false and misleading at the time they were made. Zeldes & Haeggquist is a full-service law firm which brings major class actions nationwide on behalf of defrauded investors and consumers and handles a variety of complex business litigation matters. Please visit www.zhlaw.com for more information. Contact: Zeldes & Haeggquist, LLP Amber L. Eck, 619-342-8000 email@example.com